ArticleFrontiers in veterinary science2026
Case Report: Equine allogeneic umbilical cord blood mesenchymal stromal cells (CB-MSC) as adjunctive therapy in a foal with septic arthritis and osteomyelitis.
Article in Frontiers in veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stromal cells (MSCs) are recognized for their potent anti-inflammatory, antibacterial, and immunomodulatory properties, making them a promising therapeutic option for combating antibiotic resistance and biofilm-associated infections. This report describes the successful treatment of septic arthritis and osteomyelitis in a foal using equine allogeneic cord blood-derived MSCs (CB-MSCs) in combination with antibiotic therapy. An 8-day-old Thoroughbred filly initially presented with septic arthritis of the right tibiotarsal joint, pneumonia, and omphalophlebitis/arteritis. Subsequently, the filly developed septic arthritis of the left elbow joint, epiphysitis, and osteomyelitis of the ulna, which progressed to an aggressive pathological fracture. Chloramphenicol was instituted based on the bacterial culture and susceptibility. Due to limited clinical and cytological improvement following needle lavage, arthroscopic lavage, and intra-articular antibiotic administration, the left elbow joint and fracture site were treated three times with 15 million TLR3-activated CB-MSCs in combination with meropenem (7.25 mg/kg IA). Additionally, the filly received twice systemic treatment with non-activated CB-MSCs (1 million cells/kg IV). The treatment resulted in complete resolution of both septic arthritis and osteomyelitis. At a 12-month follow-up, the filly remained sound, and radiographic re-evaluation showed significant remodeling of the ulna. This case describes the successful use of equine allogeneic cord blood-derived mesenchymal stromal cells (CB-MSCs), administered locally and systemically in combination with antibiotic therapy, to manage a refractory intra-synovial and osseous septic process in a foal. The use of TLR3-activated CB-MSCs may have supported antimicrobial treatment, highlighting the potential antimicrobial, anti-inflammatory, and immunomodulatory properties of CB-MSCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.